Stockscreener 앱 받기
205.19
0.52%
-1.08
시장 영업 전:
204.51
-0.68
-0.33%
전일 마감가:
$206.27
열려 있는:
$207.22
하루 거래량:
9.22M
Relative Volume:
1.61
시가총액:
$362.98B
수익:
$56.33B
순이익/손실:
$4.28B
주가수익비율:
85.50
EPS:
2.4
순현금흐름:
$17.83B
1주 성능:
+1.93%
1개월 성능:
-1.84%
6개월 성능:
+4.25%
1년 성능:
+13.56%
1일 변동 폭
$200.34
$207.22
1주일 범위
$200.34
$212.15
52주 변동 폭
$153.58
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
205.19 | 362.98B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
818.22 | 734.90B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
155.36 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
68.24 | 301.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
86.60 | 218.75B | 64.17B | 17.12B | 18.10B | 6.73 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Gastric Cancer Research Report 2025: A $14.5 Billion Market - GlobeNewswire
Esophageal Cancer Market research 2024-2032 Featuring AstraZeneca, Takeda, Pfizer, Novartis, Amgen, Bristol-Myers Squibb, Eli Lily and Co, Sanofi, AbbVie, and GSK - GlobeNewswire
Abbvie’s chief commercial officer sells shares worth $12.36 million - Investing.com India
AbbVie Fights Mississippi Drug Discount Law at Fifth Circuit - Bloomberg Law News
AbbVie On A STEAP Learning Curve In ADCs - insights.citeline.com
Aesthetic Injectables Market Is Booming Worldwide | AbbVie, - openPR.com
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold? - Yahoo Finance
OneAscent Financial Services LLC Buys 1,490 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
Looking At AbbVie's Recent Unusual Options Activity - Benzinga
How the Parkinson’s Disease Community and AbbVie Are Shaping the Future of Care - AbbVie
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial - Endpoints News
Centric Wealth Management Acquires 8,508 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Legal Investigation: Cerevel's $22 Share Offering Scrutinized After $45 AbbVie Buyout - Stock Titan
Decoding AbbVie's Options Activity: What's the Big Picture? - Benzinga
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
AbbVie: Margin Expansion Potential Can Support Elevated P/E (NYSE:ABBV) - Seeking Alpha
AbbVie to Host First-Quarter 2025 Earnings Conference Call - Investing News Network
Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades' - Benzinga
Colrain Capital LLC Makes New $2.75 Million Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AIA Group Ltd Lowers Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Alliancebernstein L.P. - MarketBeat
Exclusive: SV Health debuts Parkinson’s biotech with backing from AbbVie and others - Endpoints News
AbbVie Inc. (NYSE:ABBV) Shares Sold by Level Four Advisory Services LLC - MarketBeat
AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield - MSN
RWA Wealth Partners LLC Has $55.27 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week - MSN
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra - ACCESS Newswire
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (NYSE:ABBV) - Seeking Alpha
AbbVie (NYSE:ABBV) Trading Down 2.1%Here's What Happened - MarketBeat
AbbVie (ABBV) Rebounds After Consecutive Losses, Eyes Future Gro - GuruFocus.com
AbbVie shares rose after seven consecutive sessions of losses (NYSE:ABBV) - Seeking Alpha
Corticosteroids Market May See a Big Move | Major Giants- AbbVie, Astellas Pharma, AstraZeneca - openPR
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip - Yahoo Finance
Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca - Barchart
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 - PR Newswire
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income - Yahoo Finance
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market - MSN
AbbVie accuses oncology partner of stealing trade secrets - Crain's Chicago Business
AbbVie Inc (ABBV) Shares Gap Down to $202.37 on Mar 25 - GuruFocus
Smart Money Is Betting Big In ABBV OptionsAbbVie (NYSE:ABBV) - Benzinga
AbbVie sues Genmab, claiming trade secrets theft - pharmaphorum
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbvie CEO Robert A. Michael's 2024 Total Compensation Was $18.5 MillionFiling -March 24, 2025 at 04:44 pm EDT - Marketscreener.com
AbbVie files trade secrets suit against ADC competitor - Endpoints News
AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets - PharmaLive
Genmab stock falls amid AbbVie lawsuit By Investing.com - Investing.com South Africa
Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims - TipRanks
Genmab stock falls amid AbbVie lawsuit - Investing.com
AbbVie Lawsuit Alleges That Partner Genmab "Misappropriated” Trade Secrets - BioSpace
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.60%
자본화:
|
볼륨(24시간):